Confluence Pharmaceuticals signs co-development and marketing agreement with AOP Orphan for Fragile X Syndrome drug
23 March 2015 | By Victoria White
Confluence and AOP have signed an agreement to co-develop and market a product for the treatment of Fragile X Syndrome in Europe and the Middle East...